STAT Plus: Eli Lilly gets an edge against Pfizer in adjuvant breast cancer
ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME
The company said a study showed that its drug Verzenio decreased the risk of a relapse in women who had had their tumors removed.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario